DeepMind剥离出的Isomorphic Labs融资21亿美元

DeepMind spinout Isomorphic Labs raises $2.1bn

Sifted 2026-05-12 15:35 Original
摘要
DeepMind的衍生公司Isomorphic Labs成功融资21亿美元,推动其人工智能药物研发业务。此次巨额融资将加速该公司利用AI技术革新药物发现流程,可能对全球制药行业产生深远影响。

该文章仅爬取到标题,未获取到正文内容。

查看原文
Summary
Isomorphic Labs, an AI drug discovery company spun out from Google DeepMind, has raised $2.1 billion in funding. The massive investment will accelerate its use of artificial intelligence to design novel medicines, potentially transforming the pharmaceutical industry.

Only the headline was crawled; full content was not available.

Read original
Résumé
Isomorphic Labs, une spin-off de DeepMind (Google), a levé 2,1 milliards de dollars pour accélérer la découverte de médicaments par intelligence artificielle. Dirigée par Demis Hassabis, la société renforce ainsi sa position dans la recherche pharmaceutique, avec un impact majeur sur l'innovation technologique et médicale.

Seul le titre a été récupéré.

Lire l'original
AI Insight
Core Point

Isomorphic Labs raised $2.1 billion to advance AI-driven drug discovery, signaling immense investor confidence in AI’s pharmaceutical applications.

Key Players
  • Isomorphic Labs — AI drug discovery spinout from DeepMind, based in London, UK.
Industry Impact
  • Computing/AI: High — largest-ever AI drug discovery round validates the model.
  • ICT: Medium — implies growing demand for specialized cloud and data infrastructure in biotech.
Tracking

[Strongly track] — this record-setting funding could accelerate AI-driven pharma deals and reshape the competitive landscape.

Highlights
Investment / Funding
Related Companies
DeepMind
mature
positive
Isomorphic Labs
DeepMind startup
positive
Categories
人工智能 创业
AI Processing
2026-05-12 20:49
deepseek / deepseek-v4-pro